Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares dropped 25% during mid-day trading on Tuesday . The stock traded as low as C$0.02 and last traded at C$0.02. Approximately 168,000 shares were traded during trading, a decline of 7% from the average daily volume of 181,409 shares. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Stock Down 25.0 %
The company has a debt-to-equity ratio of 138.88, a current ratio of 0.09 and a quick ratio of 0.46. The stock has a market capitalization of C$1.99 million, a PE ratio of -1.50 and a beta of 0.05. The company has a 50 day moving average price of C$0.02 and a 200-day moving average price of C$0.02.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Stories
- Five stocks we like better than Aequus Pharmaceuticals
- Most active stocks: Dollar volume vs share volume
- Emerging Markets: What They Are and Why They Matter
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Recession or Not, These 3 Stocks Are Winners
- Find and Profitably Trade Stocks at 52-Week Lows
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
